Advertisement

Drugs

, Volume 73, Issue 18, pp 2053–2066 | Cite as

Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome

  • Gillian M. Keating
Adis Drug Evaluation

Abstract

The recombinant humanized monoclonal antibody eculizumab (Soliris®) is a complement inhibitor that is indicated for use in the treatment of atypical haemolytic uraemic syndrome (aHUS). This article reviews the clinical efficacy and tolerability of eculizumab in the treatment of patients with aHUS, as well as summarizing its pharmacological properties. Intravenous eculizumab inhibited complement-mediated thrombotic microangiopathy in patients aged ≥12 years with aHUS, according to the results of two noncomparative, multinational, 26-week, phase II trials. At 26 weeks, the platelet count was significantly increased in patients with progressing thrombotic microangiopathy despite plasma exchange/infusion, and thrombotic microangiopathic event-free status was achieved in 80 % of patients with a long disease duration and chronic kidney disease who received long-term plasma exchange/infusion. Renal function and health-related quality of life also improved with eculizumab therapy in both studies. Outcomes were maintained or further improved throughout 2 years of follow-up. Eculizumab was also effective in adult and paediatric patients with aHUS, according to the results of additional prospective or retrospective trials. Intravenous eculizumab was generally well tolerated in patients with aHUS. Eculizumab is associated with an increased susceptibility to meningococcal infection, so patients should be immunized with meningococcal vaccine. In conclusion, eculizumab is a valuable new agent for use in the treatment of aHUS.

Keywords

Chronic Kidney Disease Paroxysmal Nocturnal Haemoglobinuria Eculizumab Thrombotic Microangiopathy Meningococcal Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was also offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

References

  1. 1.
    Westra D, Wetzels JFM, Volokhina EB, et al. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Neth J Med. 2012;70(3):121–9.PubMedGoogle Scholar
  2. 2.
    Taylor CM, Machin S, Wigmore SJ, et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol. 2010;148(1):37–47.PubMedCrossRefGoogle Scholar
  3. 3.
    Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009;24(4):687–96.PubMedCrossRefGoogle Scholar
  4. 4.
    Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60.PubMedCrossRefGoogle Scholar
  5. 5.
    Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Hodgkins KS, Bobrowski AE, Lane JC, et al. Clinical grand rounds: atypical hemolytic uremic syndrome. Am J Nephrol. 2012;35(5):394–400.PubMedCrossRefGoogle Scholar
  7. 7.
    Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26(1):41–57.PubMedGoogle Scholar
  8. 8.
    Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554–62.PubMedCrossRefGoogle Scholar
  9. 9.
    Langman C. Systemic multi-organ complications in atypical hemolytic uremic syndrome (aHUS): retrospective study in a medical practice setting [abstract no. 0490]. Haematologica. 2012;97(Suppl. 1):195–6.Google Scholar
  10. 10.
    Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676–87.PubMedCrossRefGoogle Scholar
  11. 11.
    Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8(11):643–57.PubMedCrossRefGoogle Scholar
  12. 12.
    Schmidtko J, Peine S, El-Housseini Y, et al. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis. 2013;61(2):289–99.PubMedCrossRefGoogle Scholar
  13. 13.
    European Medicines Agency. Soliris (eculizumab): EU summary of product characteristics. 2011. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000791/WC500054208.pdf. Accessed 8 Oct 2013.
  14. 14.
    Alexion Pharmaceuticals Inc. Soliris® (eculizumab): US prescribing information. 2012. http://soliris.net/sites/default/files/assets/soliris_pi.pdf. Accessed 8 Oct 2013.
  15. 15.
    Alexion. Alexion’s Soliris (eculizumab) receives marketing approval in Japan for all patients with aHUS [media release]. 2013. http://news.alexionpharma.com/press-release/product-news/alexions-soliris-eculizumab-receives-marketing-approval-japan-all-patient. Accessed 25 Oct 2013.
  16. 16.
    Alexion Pharma Canada Corp. Alexion’s Soliris (eculizumab) received marketing approval in Canada for patients with atypical HUS [media release]. 2013. http://www.alexionpharm.com. Accessed 25 Oct 2013.
  17. 17.
    McKeage K. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria. Drugs. 2011;71(17):2327–45.PubMedCrossRefGoogle Scholar
  18. 18.
    Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol Adv Appl. 2011;3:5–12.CrossRefGoogle Scholar
  19. 19.
    Nürnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360(5):542–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Fernández-de Larrea C, Cofan F, Oppenheimer F, et al. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation. 2010;89(7):903–4.Google Scholar
  21. 21.
    Chatelet V, Fremeaux-Bacchi V, Lobbedez T. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant. 2009;9:2644–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Ohanian M, Cable C, Halka K. Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report. Clin Pharmacol. 2011;3:45–50.PubMedGoogle Scholar
  23. 23.
    Legault DJ, Boelkins MR. Successful treatment of aHUS recurrence and arrest of plasma exchange resistant TMA post-renal transplantation with the terminal complement inhibitor eculizumab [abstract no. 2421]. Blood. 2009;114(22 Suppl).Google Scholar
  24. 24.
    Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12(12):3337–54.PubMedCrossRefGoogle Scholar
  25. 25.
    Prescott HC, Wu HM, Cataland SR, et al. Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. Am J Hematol. 2010;85(12):976–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Povey H, Vundru R, Junglee N, et al. Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis. Clin Nephrol. 2013;. doi: 10.5414/CN107958.PubMedGoogle Scholar
  27. 27.
    Gras K, Koch M, Nashan B, et al. Eculizumab improves atypical HUS in a patient after kidney transplantation [abstract]. Transpl Int. 2011;24(Suppl 3):37–8.Google Scholar
  28. 28.
    Heyne N, Weitz M, Guthoff M, et al. Terminal complement blockade by eculizumab effectively reverses recurrent atypical hemolytic uremic syndrome after kidney transplantation [abstract]. Transpl Int. 2011;24(Suppl 3):35.Google Scholar
  29. 29.
    Vilalta R, Lara E, Madrid A, et al. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol. 2012;27(12):2323–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Al-Akash SI, Almond PS, Savell VH Jr, et al. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol. 2011;26(4):613–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360(5):544–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Jungraithmayr TC, Hofer J, Mark W, et al. Successful renal transplantation in a 10 year old boy with factor h associated atypical hemolytic uremic syndrome (aHUS) with plasmapheresis and eculizumab [abstract]. Pediatr Transplant. 2009;13(Suppl):109.Google Scholar
  33. 33.
    Gulleroglu K, Fidan K, Hancer VS, et al. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol. 2013;28(5):827–30.PubMedCrossRefGoogle Scholar
  34. 34.
    Giordano M, Castellano G, Messina G, et al. Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report. Pediatrics. 2012;130(5):e1385–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Somers MJG, Rodig NM. Successful treatment of recurrent atypical hemolytic-uremic syndrome with eculizumab after pediatric kidney transplantation [abstract]. Pediatr Transplant. 2011;15(Suppl):82.Google Scholar
  36. 36.
    Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33(17–18):1389–401.PubMedCrossRefGoogle Scholar
  37. 37.
    Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnol. 2007;25(11):1256–64.CrossRefGoogle Scholar
  38. 38.
    Goicoechea de Jorge E, Macor P, Paixao-Cavalcante D, et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol. 2011;22(1):137–45.Google Scholar
  39. 39.
    Legendre C, Greenbaum L, Sheerin N, et al. Efficacy of eculizumab in patients with atypical hemolytic uremic syndrome (aHUS) with or without prior renal transplant: an integrated analysis of two prospective phase II trials [poster]. European Renal Association-European Dialysis & Transplant Association 50th Congress, 18–21 May 2013, Istanbul.Google Scholar
  40. 40.
    European Medicines Agency. Soliris (eculizimab): EU assessment report. 2011. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000791/WC500119185.pdf. Accessed 8 Oct 2013.
  41. 41.
    Lapeyraque A-L, Simonetti G, Vilalta R, et al. Efficacy and safety of eculizumab treatment for atypical hemolytic uremic syndrome (aHUS) in pediatric patients: outcomes from a retrospective study [abstract no. 095]. Canadian Society of Nephrology Annual Meeting, 25–30 Apr 2012, St. John’s (NL).Google Scholar
  42. 42.
    Fakhouri F, Hourmant M, Campistol JM, et al. Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in adult atypical hemolytic uremic syndrome (aHUS) patients (pts) [abstract]. Kidney Week 2013, 5–10 Nov 2013, Atlanta (GA).Google Scholar
  43. 43.
    Greenbaum LA, Fila M, Tsimaratos M, et al. Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in pediatric atypical hemolytic uremic syndrome (aHUS) patients (pts) [abstract]. Kidney Week 2013, 5–10 Nov 2013, Atlanta (GA).Google Scholar
  44. 44.
    Vilalta R, Al-Akash SI, Davin J, et al. Eculizumab therapy for pediatric patients with atypical hemolytic uremic syndrome: efficacy and safety outcomes of a retrospective study [abstract no. 1155]. Haematologica. 2012;97(Suppl 1):479.Google Scholar
  45. 45.
    Davin J-C, Groothoff JW, Bemelman FJ, et al. Maintenance of renal function under eculizumab despite discontinuation of plasma exchange after a third transplantation for atypical hemolytic uremic syndrome associated with a CFH mutation [abstract]. Pediatr Transplant. 2011;15(Suppl):52.Google Scholar
  46. 46.
    David R, Hochberg-Klein S, Amer R. Resolution of ocular involvement with systemic eculizumab therapy in atypical hemolytic-uremic syndrome. Eye (Lond). 2013;27(8):997–8.CrossRefGoogle Scholar
  47. 47.
    Dorresteijn EM, van de Kar NC, Cransberg K. Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count. Pediatr Nephrol. 2012;27(7):1193–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Greenbaum L, Legendre CM, Babu S, et al. Eculizumab (ECU) in atypical hemolytic uremic syndrome (aHUS) patients with progressing thrombotic microangiopathy (TMA): 2-year data [abstract no. 2084]. Blood. 2012;120.Google Scholar
  49. 49.
    Legendre C, Babu S, Cohen D, et al. Efficacy of eculizumab in atypical hemolytic uremic syndrome (aHUS) patients with or without dialysis at baseline [poster]. European Renal Association-European Dialysis & Transplant Association 50th Congress, 18–21 May 2013, Istanbul.Google Scholar
  50. 50.
    Licht C, Muus P, Legendre CM, et al. Eculizumab (ECU) safety and efficacy in atypical hemolytic uremic syndrome (aHUS) patients with long disease duration and chronic kidney disease (CKD): 2-year results [abstract no. 985]. Blood. 2012;120.Google Scholar
  51. 51.
    Licht C, Muus P, Legendre C, et al. Eculizumab in aHUS patients with a long disease duration and chronic kidney disease: 2-year follow-up [poster]. World Congress of Nephrology, 31 May–4 Jun 2013, Hong Kong.Google Scholar
  52. 52.
    Ardissino G, Wally Ossola M, Maria Baffero G, et al. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol. 2013;122(2 Pt 2):487–9.Google Scholar
  53. 53.
    Kelly R, Arnold L, Richards S, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol. 2010;149(3):446–50.PubMedCrossRefGoogle Scholar
  54. 54.
    Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program. 2012;2012:617–25.PubMedGoogle Scholar
  55. 55.
    Fakhouri F, Fremeaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Eur J Intern Med. 2013;24(6):492–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Alexion Pharmaceuticals. aHUS observational long term follow-up (LTFU) [ClinicalTrials.gov identifier NCT01522170] US National Institutes of Health. Clinical Trials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01522170. Accessed 8 Oct 2013.
  57. 57.
    Riedl M, Hofer J, Rosales A, et al. Successful renal transplantation in a child with factor H associated atypical hemolytic uremic syndrome (aHUS) with prophylactic eculizumab treatment [abstract no. 510]. 15th Congress of the International Pediatric Nephrology Association, 29 Aug–2 Sep 2010, New York (NY).Google Scholar
  58. 58.
    Xie L, Nester CM, Reed AI, et al. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transplant Proc. 2012;44(10):3037–40.PubMedCrossRefGoogle Scholar
  59. 59.
    Krid S, Roumenina LT, Beury D, et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant. 2012;12(7):1938–44.PubMedCrossRefGoogle Scholar
  60. 60.
    Nester C, Stewart Z, Myers D, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2011;6(6):1488–94.PubMedCrossRefGoogle Scholar
  61. 61.
    Weitz M, Amon O, Bassler D, et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011;26(8):1325–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Alexion Pharmaceuticals. Atypcial hemolytic-uremic syndrome (aHUS) registry [ClinicalTrials.gov identifier NCT01522183] US National Institutes of Health. Clinical Trials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01522183. Accessed 8 Oct 2013.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisNorth ShoreNew Zealand

Personalised recommendations